In hematologic malignancies, treatment of CRS often targets elevated cytokines (most elevated cytokines typically seen are IL-10, IL-6 and INF- γ) and is managed using corticosteroids interleukin-6 blockade (32, 33). Here, IL6 is linked to hematologic disorder.